GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Valuation Rank

Genexine (XKRX:095700) Valuation Rank


View and export this data going back to 2009. Start your Free Trial

What is Genexine Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Genexine Valuation Rank Related Terms

Thank you for viewing the detailed overview of Genexine's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Valuation Rank
Comparable Companies
XKRX:228760 XKRX:216080 XKRX:323990 XKRX:334970 XKRX:005690 XKRX:358570 XKRX:199800 XKRX:115450 XKRX:060590 XKRX:011000 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488
Website
http://www.genexine.com
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.